Blood Sample Markers of Reproductive Hormones in Assessing Ovarian Reserve in Younger Patients With Newly Diagnosed Lymphomas

Prior treatment

• Patients who have previously received chemotherapy other than steroids and intrathecal chemotherapy are not eligible
• Patients in whom planned therapy includes: removal or uterus or ovary(ies), pelvic irradiation, cranial irradiation or hematopoietic stem cell transplantation are not eligible
• Patients who previously have had their uterus or ovary(ies) removed are not eligible
• Patients who have received gonadotropin release hormone agonist or antagonist (e.g. Lupron) prior to study entry are not eligible
• Patients who have undergone or are planning to undergo ovarian tissue, oocyte or embryo cryopreservation prior to treatment are not eligible

Other illness

• Patients who have a secondary malignancy are not eligible
• Patients with known history of ovarian disease: e.g. Turner syndrome or polycystic ovarian syndrome are not eligible

Other

• Patients who are pregnant or breast feeding are not eligible

• Patients must have had first menses \>= 6 months prior to enrollment
• Patients must be newly diagnosed with lymphoma; this includes but is not limited to Hodgkin lymphoma, Burkitts lymphoma, diffuse large B cell lymphoma, and anaplastic large cell lymphoma
• Planned cancer treatment must include an alkylating agent: i.e. procarbazine, cyclophosphamide, ifosphamide; planned cancer treatment must be less than one year
• Patients with any performance status are eligible for enrollment
• Patients may take hormone medications excluding gonadotropin-releasing hormone (GnRH) analogues
• All patients and/or their parents or legal guardians must sign a written informed consent
• All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met